R&D channel feed

Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Last year

FDA asks Citius for en­hanced prod­uct test­ing in CRL for non-Hodgkin lym­phoma drug Lym­phir

Last year

Sum­it­o­mo and Ot­su­ka schiz­o­phre­nia as­set flunks PhI­II, com­pa­nies blame Covid-19 in­duced place­bo ef­fect

Last year

Mer­ck touts topline PhI­II Keytru­da da­ta in pre-surgery breast can­cer treat­ment

Last year
Pharma

Sanofi, BioN­Tech cut ear­ly-stage mR­NA can­cer ther­a­py from pipeline

Last year
Pharma

Ho­mol­o­gy shut­ters de­vel­op­ment as ge­net­ic med­i­cines biotech flash­es ‘for sale’ sign, lays off 80 em­ploy­ees

Last year
People
Cell/Gene Tx

Take­da re­veals PhII fail for rare ge­net­ic con­di­tion, looks to new prod­uct pipeline to bol­ster growth

Last year
Pharma

Ako­rn’s bank­rupt­cy, re­calls bring a drug to treat lead poi­son­ing in­to short­age

Last year
Manufacturing

In two late-stage tri­als of Lil­ly’s tirzepatide, par­tic­i­pants lost one-quar­ter of their weight

Last year

'An un­holy union': Stan­ford sci­en­tists cre­ate a drug that flips can­cer dri­ver in­to killer

Last year

Mer­sana halves work­force in light of ovar­i­an can­cer tri­al flop, spelling end to its lead ADC

Last year
People

Af­ter years of de­lay, Roche takes one of Spark’s he­mo­phil­ia gene ther­a­pies in­to PhI­II, drops an­oth­er

Last year
Cell/Gene Tx

‘This is not a sci­ence prob­lem any­more': Paths emerge for scal­ing up rare dis­ease med­i­cine

Last year
In Focus

Lari­mar to kick off high­er dose of lead rare dis­ease drug, ini­ti­ate OLE tri­al

Last year
FDA+

Hu­mani­gen warns of bank­rupt­cy af­ter fail­ing to bounce back from Covid-19 EUA re­jec­tion 

Last year
Pharma

Stoke Ther­a­peu­tics un­veils more da­ta on stud­ies of Dravet drug, hint­ing at im­prove­ments to cog­ni­tion and be­hav­ior

Last year

As Am­gen ac­qui­si­tion faces on­go­ing suit, Hori­zon's mid-stage lu­pus tri­al fails

Last year

Bio­Car­dia paus­es en­roll­ment in PhI­II tri­al of heart fail­ure stem cell ther­a­py

Last year

Ko­di­ak ends at­tempt at an Eylea ri­val as its bi­o­log­ic fails two of three PhI­II tri­als

Last year

Gilead ax­es PhI­II tri­al for CD47 drug in lat­est set­back for $4.9B buy­out

Last year

Bavar­i­an Nordic scraps RSV vac­cine af­ter PhI­II tri­al miss­es the bar on pre­vent­ing se­vere symp­toms

Last year

Codex­is cuts 25% of staff, slash­es drug pro­grams while dou­bling down on RNAi tech

Last year
People

Af­ter sev­en pa­tient deaths, ADC gets par­tial hold and de­cides to stop Zyn­lon­ta tri­al

Last year
FDA+

J&J down­sizes in­fec­tious dis­ease and vac­cine pipeline, cut­ting he­pati­tis B pro­grams

Last year
Pharma
First page Previous page 77787980818283 Next page Last page
A service from the Financial Times